As of June 7, 2025, Gilead Sciences Inc (GILD) reports a Gross Margin of 78.26%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Gilead Sciences Inc's Gross Margin
Over recent years, Gilead Sciences Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 78.26% |
| 2023-12-31 | 77.80% |
| 2022-12-31 | 79.26% |
| 2021-12-31 | 75.82% |
| 2020-12-31 | 81.48% |
This slight downward trend highlights how Gilead Sciences Inc manages its operational efficiency and pricing power over time.
Comparing Gilead Sciences Inc's Gross Margin to Peers
To better understand Gilead Sciences Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Gilead Sciences Inc (GILD) | 78.26% |
| Fate Therapeutics Inc (FATE) | 7775.20% |
| CRISPR Therapeutics AG (CRSP) | 7775.20% |
| Sana Biotechnology Inc (SANA) | 7775.20% |
| Kodiak Sciences Inc (KOD) | 7775.20% |
| Intellia Therapeutics Inc (NTLA) | 7775.20% |
Compared to its competitors, Gilead Sciences Inc's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.